Dark

Check out our Dark Pool Levels

NKTX
Nkarta, Inc. Common Stock
stock NASDAQ

At Close

Oct 1, 2026 4:00:01 PM EDT

2.56USD-2.290%(-0.06)402,298

0.00Bid 0.00Ask 0.00Spread

Pre-market

Sep 28, 2026 9:22:30 AM EDT

2.78USD+6.107%(+0.16)0

After-hours

Oct 1, 2026 4:30:30 PM EDT

2.53USD-1.172%(-0.03)542

OverviewOptionsHistoricalExchangesShortsTrends

NKTX Reddit Mentions

Subreddits

Limit Labels Price

We have sentiment values and mention counts going back to 2017. The complete data set is available via the API.

Take me to the API

NKTX Specific Mentions

As of Oct 2, 2026 8:39:22 AM EDT (<1 min. ago)

Includes all comments and posts. Mentions per user per ticker capped at one per hour.

21 hr ago • u/HunterMichael92 • r/investing • nkarta_inc_positive_poster_presentation_debt_free • B

Nkarta, Inc. is preparing to release results from the NTRUST-1/2 Trials related to Myositis and Scleroderma at the ACR Conference, they were awarded a Safety Presentation as well on the efficacy and 0 side-effect therapies they have been dosing patients.
CEO Paul Hastings on Stifel's investor forum questioned multiple aspects of their progress to date and both Hastings and President reinforced their findings and excitement to release not only results but durability of the drug.
Their stock is currently trading at $2.56 below cash value and a healthy pipeline to get past results and into FDA track for approval.
I am long 180,000 shares as of today, and will increase position ahead of the November readout.
They have a 3 year cash runway, with no debt, and no sensitivity to current interest rate forecast.
$NKTX

21 hr ago • u/HunterMichael92 • r/investing • nkarta_inc_positive_poster_presentation_debt_free • B

Nkarta, Inc. is preparing to release results from the NTRUST-1/2 Trials related to Myositis and Scleroderma at the ACR Conference, they were awarded a Safety Presentation as well on the efficacy and 0 side-effect therapies they have been dosing patients.
CEO Paul Hastings on Stifel's investor forum questioned multiple aspects of their progress to date and both Hastings and President reinforced their findings and excitement to release not only results but durability of the drug.
Their stock is currently trading at $2.56 below cash value and a healthy pipeline to get past results and into FDA track for approval.
I am long 180,000 shares as of today, and will increase position ahead of the November readout.
They have a 3 year cash runway, with no debt, and no sensitivity to current interest rate forecast.
$NKTX

Share